Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

被引:55
作者
Kramer, JR [1 ]
Giordano, TP
Souchek, J
El-Serag, HB
机构
[1] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA
[2] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA
[3] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA
[4] Baylor Coll Med, Gastroenterol Sect, Dept Med, Houston, TX 77030 USA
关键词
hepatitis C virus; HIV coinfection; fulminant hepatic failure; Veterans Affairs Medical Center; retrospective cohort study; highly active antiretroviral therapy;
D O I
10.1016/j.jhep.2004.11.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: It is uncertain if patients coinfected with hepatitis C and HIV are more likely to suffer fulminant hepatic failure (FHF) when compared to patients with HIV-only. Methods: We conducted a retrospective cohort study using national administrative databases from the Department of Veterans Affairs in patients hospitalized for the first time with HIV and/or hepatitis C between 10/1991 and 9/2000. Fulminant hepatic failure was defined as occurring after the index hospitalization through 9/2001 in the absence of preexisting liver disease. We calculated incidence rates, Kaplan Meier cumulative incidence curves, and Cox proportional hazards ratios while adjusting for demographics and other potential confounders. Results: We identified 11,678 patients with HIV-only and 4761 patients with coinfection. There were 92 cases of fulminant hepatic failure yielding an incidence rate of 1.1/1000 person-years and 2.5/1000 person-years in the HIV-only and coinfected groups. The cumulative incidence of fulminant hepatic failure in the coinfected group was higher than in the HIV-only group (P < 0.0001). The risk of fulminant hepatic failure in patients with coinfection compared to HIV-only during the HAART era was several folds higher than that during the pre-HAART era. Conclusions: HAART and hepatitis C coinfection appeared to act synergistically in HIV-infected patients to increase the risk of fulminant hepatic failure, a rare but often fatal disease. (c) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 23 条
[1]  
Barbaro G, 1999, AM J GASTROENTEROL, V94, P2198, DOI 10.1111/j.1572-0241.1999.01294.x
[2]   Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].
Bozzette, SA ;
Ake, CF ;
Tam, HK ;
Chang, SW ;
Louis, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710
[3]   Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection [J].
den Brinker, M ;
Wit, FWNM ;
Wertheim-van Dillen, PME ;
Jurriaans, S ;
Weel, J ;
van Leeuwen, R ;
Pakker, NG ;
Reiss, P ;
Danner, SA ;
Weverling, GJ ;
Lange, JMA .
AIDS, 2000, 14 (18) :2895-2902
[4]   Assessment of vital status in Department of Veterans Affairs national databases: Comparison with state death certificates [J].
Dominitz, JA ;
Maynard, C ;
Boyko, EJ .
ANNALS OF EPIDEMIOLOGY, 2001, 11 (05) :286-291
[5]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[6]   Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine [J].
Gisolf, EH ;
Dreezen, C ;
Danner, SA ;
Weel, JLF ;
Weverling, GJ .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) :1234-1239
[7]   Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? [J].
John, M ;
Flexman, J ;
French, MAH .
AIDS, 1998, 12 (17) :2289-2293
[8]  
Klein JP., 1997, SURVIVAL ANAL TECHNI, V149, P95
[9]   Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution [J].
Martín-Carbonero, L ;
Núñez, M ;
Ríos, P ;
Pérez-Olmeda, M ;
González-Lahoz, J ;
Soriano, V .
AIDS, 2002, 16 (10) :1423-1425
[10]   Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy [J].
Martínez, E ;
Blanco, JL ;
Arnaiz, JA ;
Pérez-Cuevas, JB ;
Mocroft, A ;
Cruceta, A ;
Marcos, MA ;
Milinkovic, A ;
García-Viejo, MA ;
Mallolas, J ;
Carné, X ;
Phillips, A ;
Gatell, JM .
AIDS, 2001, 15 (10) :1261-1268